Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107751 | 1.00 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9107746 | 1.00 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9911756 | 0.86 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9111346 | 0.86 | CASP3 (0.36) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9111324 | 0.86 | CASP3 (0.36) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9110633 | 0.85 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9110615 | 0.85 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9107104 | 0.85 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9107108 | 0.85 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DCASP3 | |
| SCHEMBL9108286 | 0.85 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646028-B1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-11-12 | — | — | EP | claimed |
| EP-2646028-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| US-8288555-B2 | Alkene derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2012-10-16 | — | — | US | claimed |
| US-20120142740-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2012074898-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| EP-2646028-B1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2646028-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8288555-B2 | Alkene derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120142740-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074898-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142740-A1 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR3 | PDE4A 447/4885PDE4B 539/4885PDE4C 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.